Evaluation of Approved and Investigational Contact Lenses
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32205
- Dr. James Weber & Associates, PA
-
Jacksonville, Florida, United States, 32250
- Vue Optical Boutique
-
-
Michigan
-
East Lansing, Michigan, United States, 48823
- VisionCare Associates
-
-
South Carolina
-
Pickens, South Carolina, United States, 29671
- Pickens Family Eye Care
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- William J. Bogus, OD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Potential subjects must satisfy all of the following inclusion criteria to be enrolled in the study:
- The subject must read and sign the Informed Consent form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Healthy adult males or females age ≥18 and ≤49 years of age with signed informed consent. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them.
- The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 6.00 Diopter (D).
- The subject's refractive cylinder must be ≤ 1.00D in each eye.
- The subject must have visual acuity best correctable to 20/25+3 or better for each eye.
- Subjects must own a wearable pair of spectacles.
- The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of Daily Wear per day, at least 5 days per week, for a minimum of 1 month prior to the study) and willing to wear the study lenses on a similar basis.
- Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week
The subject must have normal eyes (i.e., no ocular medications or infections of any type).
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
- Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
- Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral (e.g., Chlor-Trimeton, and Benadryl) and ophthalmic antihistamines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol), systemic steroids, and any prescribed or over the counter (OTC) ocular medication.
- Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion.
- Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), LASIK, etc.).
- Any Grade 3 or greater slit lamp findings (e.g.., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
- Any known hypersensitivity or allergic reaction to Optifree®PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution
- Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study.
- Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
- Toric, extended wear, monovision or multi-focal contact lens correction.
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Participation in clinical trials involving the Test lens within 3 months prior to study enrollment.
- History of binocular vision abnormality or strabismus.
- Employee, relative or friends of employees of any ophthalmic company, or investigational clinic (e.g., Investigator, Coordinator, Technician).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TEST/CONTROL/CONTROL
Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old.
Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis.
Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
|
ACUVUE OASYS
senofilcon A with new UV blocker
|
|
Experimental: CONTROL/TEST/TEST
Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old.
Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis.
Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
|
ACUVUE OASYS
senofilcon A with new UV blocker
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Comfort
Time Frame: 2-Week Follow-up
|
Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
The average comfort score from the 3 study periods was reported.
|
2-Week Follow-up
|
|
Distance Monocular LogMAR Visual Acuity
Time Frame: 2-Week Follow-up
|
Distance Monocular LogMAR visual acuity was assessed at 4 meters using an ETDRS chart at the 2-week follow-up for each subject eye during each of the three study periods.
The average visual acuity for each lens type from the 3 study periods was reported.
|
2-Week Follow-up
|
|
Contact Lens Fitting Acceptance Rate
Time Frame: Up to 2-Week Follow-up
|
Contact lens fitting acceptance was assessed for each subject eye using a biomicroscope at post lens insertion and the 2-week follow-up.
Lens fit was a binary variable where acceptable lens fit=1 and unacceptable lens fit=0.
The proportion of eyes with acceptable lens fit was reported for each lens.
The lens fit acceptance rate for both post lens fitting at the 2-week follow-up was reported for each lens type.
|
Up to 2-Week Follow-up
|
|
Number of Grade 3 or Higher Slit Lamp Findings
Time Frame: Up to 2-Week Follow-up
|
Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e.
Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
This was performed on each subject eye at every study visit (baseline, unscheduled visits and 2-week follow-up).
The data was then dichotomized into two groups.
Those with grade 3 or higher and those with grade 2 or lower.
The number of SLF with grade 3 or higher by lens was reported.
|
Up to 2-Week Follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Quality of Vision
Time Frame: 2-Week Follow-up
|
Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
The average vision score from the 3 study periods was reported.
|
2-Week Follow-up
|
|
Overall Handling
Time Frame: 2-Week Follow-up
|
Overall Handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
The average handling score from the 3 study periods was reported.
|
2-Week Follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CR-5960
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visual Acuity
-
NCT06431295Not yet recruiting
-
NCT05814367Completed
-
NCT05601544Completed
-
NCT04954833Completed
-
NCT03733899Completed
-
NCT00759096Completed
-
NCT03995355Completed
Clinical Trials on CONTROL
-
NCT07313956Enrolling by invitationCritical Illness | Respiratory Failure | Mechanical Ventilation
-
NCT02453906Completed
-
NCT00961168Withdrawn
-
NCT06352619Recruiting
-
NCT04084873UnknownChronic Pain | Fibromyalgia
-
NCT01422421CompletedCoronary Artery Disease | Hypertension | Type 2 Diabetes | Dyslipidemia
-
NCT03896490CompletedVery Premature Baby
-
NCT03605303TerminatedRefractive Error Correction
-
NCT05563779CompletedRespiratory Failure